JDD December 2023 Issue Highlights
Welcome to the December 2023 issue of the Journal of Drugs in Dermatology (JDD), where cutting-edge research and advancements in the field of dermatology take center stage. This issue brings together a diverse array of original articles, case reports, brief communications, and letters to the editor and delves into the latest developments, therapeutic breakthroughs, and cl …
Welcome to the December 2023 issue of the Journal of Drugs in Dermatology (JDD), where cutting-edge research and advancements in the field of dermatology take center stage. This issue brings together a diverse array of original articles, case reports, brief communications, and letters to the editor and delves into the latest developments, therapeutic breakthroughs, and cl … 
Pustular psoriasis can present quickly and pose a life-threatening emergency. Acitretin is the only systemic retinoid FDA-approved for treatment of psoriasis, specifically both pustular and severe plaque-type psoriasis.1Systemic retinoids such as acitretin are utilized heavily in dermatology, and practitioners must be knowledgeable about all of the FDA-approved and off-label applications as well a … 
JDD authors Amelia M. Abbott-Frey BA, Alexandra J. Coromilas MD, George W. Niedt MD, and Jesse M. Lewin MD report a case of linear porokeratosis with recurrent malignant degeneration to squamous cell carcinoma (SCC) recurring six years after excision of initial SCC.
Case Report
A 79-year-old woman with a history of hypertension and hypothyroidism presented with a friable tumor within a lesion o … 
Authors Julie K. Nguyen MD, Silvia Mancebo MD, Brady Bleicher MD, and Jared Jagdeo MD MS present a case report of a patient with localized porokeratosis lesions on the face and extremities. Brought to you by the Journal of Drugs in Dermatology, a product of SanovaWorks.
Introduction
Porokeratosis is a disorder of epidermal keratinization that encompasses multiple clinical variants based on d … 